XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) director and CEO Hugh Rogers was a featured guest on two different video interviews. In both interviews, Rogers shared key information and updates about XPhyto, a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. During his InvestorIntel interview with host Peter Clausi, Rogers mentioned that the company had recently received European approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system called Covid-ID Lab, which is now registered within the European Union as a commercial in vitro diagnostic (“CE-IVD”) test. During the interview, Rogers noted that the company had gone from concept to commercial approval in less than 12 months, which is “unheard of in the biotech world.” Covid-Lab provides testing results within 25 minute of obtaining a sample, combining the speed of a rapid screening test with the accuracy of a PCR diagnostic. In an interview with Agoracom, Rogers explained how the company was advancing a number of programs simultaneously through three divisions to develop science-driven solutions solving health issues in the infectious disease screening market and how they are administered. Specifically, Rogers noted the company is working on psychedelic compounds to treat multiple mental health issues, as well as a variety of products focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. “XPhyto is a technology life science accelerator. We are advancing a number of different programs,” said XPhyto director and CEO Seth Rogers during the interview. “And first and foremost right now, taking our rapid point-of-care PCR test to markets. So we are approved in Europe for sales, and we have news coming soon in terms of distribution and partnerships and pilot products. But as you just mentioned, we have announced a shipment of 2,000 units to Israel, and that’s for the purpose of regulatory approval in Israel, looking to expand beyond Europe. So we do have a strong footprint in Germany — obviously Germany, Switzerland, Austria — the German-speaking countries would be a natural, as well as some of the larger markets, Italy, Spain, the UK in Europe. But certainly Israel, being a leader in the management and fight against COVID-19 on the testing front, on the vaccine front, it was a natural for us, being so close to Europe, to look to that market as the next step.”
To view the full video interviews, visit https://ibn.fm/lIpFu and https://ibn.fm/Hed2G
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
